Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Immunother Cancer

Supplementary Appendix

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

Tarhini et al,

Table of Contents **Page**

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Immunother Cancer

Figure S1. Kaplan-Meier plots of relapse free survival (RFS) [Figure S1A: 5-year RFS 49% (95% CI: 45%-52%) versus 41% (95% 31%-50%)] and overall survival (OS) [Figure S1B] with Grade 1-4 irAEs versus no irAE, respectively.

Figure S1A

| Gr14_AE	0-1	1-2	2-3	3-4	4-5	5-6	6-7	7-8
No	115	64	50	41	34	12	3	0
Ye	896	600	482	416	333	148	36	1

(# at risk)

3

Figure S1B

	Gr14_AE	0-1	1-2	2-3	3-4	4-5	5-6	6-7	7-8
	No	115	105	91	80	68	39	12	2
	Ye	896	825	745	662	594	358	161	27

Time Interval

(# at risk)

4

Table S5. Multivariate models: irAE CTCAE Grade 1-2 or Grade 1-4 versus Grade 0.

Variable	Hazard Ratio	95% CI	*P*-value
(a) RFS outcomes in the multivariate model for **any** irAE Grade 1-2			
irAE	0.75	0.5, 1.03	0.072
Age	1.31	1.01, 1.69	0.039
Gender	0.73	0.55, 0.97	0.030
Stage	1.33	1.10, 1.60	0.002
Clark	1.50	1.21, 1.85	< 0.001
(b) RFS outcomes in the multivariate model for **any** irAE Grade 1-4			
irAE	0.73	0.55, 0.99	0.041
Age	1.26	1.02, 1.54	0.030
Stage	1.34	1.16, 1.54	< 0.001
Thickness	1.31	1.05, 1.65	0.019
Clark	1.27	1.07, 1.50	0.006
(c) RFS outcomes in the multivariate model for **rash** irAE Grade 1-2			
Rash	0.71	0.57, 0.87	0.001
Age	1.31	1.01, 1.62	0.013
Thickness	1.29	1.02, 1.63	0.036
Clark	1.31	1.10,1.56	0.003
PS	1.31	1.01, 1.70	0.041
Stage	1.36	1.17,1.57	<0.001
(d) OS outcomes in the multivariate model for **rash** irAE Grade 1-2			
Rash	0.72	0.55, 0.96	0.024
Age	1.38	1.04, 1.82	0.025
Clark level	1.40	1.13, 1.74	0.002
(e) RFS outcomes in the multivariate model for **rash** irAE Grade 1-4			
Rash	0.71	0.58, 0.88	0.001

5

Age	1.25	1.02, 1.54	0.032
Thickness	1.29	1.02, 1.63	0.018
Clark	1.28	1.08,1.51	0.005
PS	1.26	0.97, 1.62	0.080
Stage	1.34	1.16,1.54	<0.001
(f) OS outcomes in the multivariate model for **rash** irAE Grade 1-4			
Rash	0.76	0.58, 1.00	0.047
Age	1.29	0.98, 1.69	0.067
Clark	1.33	1.06, 1.67	0.015
Thickness	1.29	0.95, 1.75	0.094
(g) RFS outcomes in the multivariate model for **rash and endocrine** irAE Grade 1-2			
Endocrine	0.68	0.54, 0.84	<0.001
Age	1.29	1.04, 1.61	0.024
Gender	0.77	0.60, 0.98	0.031
Stage	1.34	1.16, 1.58	<0.001
Clark	1.40	1.18, 1.67	<0.001
PS	1.30	0.99, 1.71	0.057
(h) OS outcomes in the multivariate model for **rash and endocrine** irAE Grade 1-2			
Rash and endocrine	0.68	0.51, 0.92	0.008
Age	1,33	0.99, 1.79	0.014
Gender	0.75	0.54, 1.04	0.080
Clark	1.38	1.10, 1.74	0.006
(i) RFS outcomes in the multivariate model for **rash and endocrine** irAE Grade 1-4			
Rash and endocrine	0.71	0.55, 0.91	0.008
Age	1.28	1.03, 1.55	0.028
Thickness	1.31	1.04, 1.64	0.021
Stage	1.33	1.16, 1.54	<0.001
Clark	1.26	1.07, 1.49	0.007
PS	1.24	0.96, 1.59	0.010
(j) OS outcomes in the multivariate model for **rash and endocrine** irAE Grade 1-4			
Rash and endocrine	0.76	0.58, 1.00	0.054

6

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Immunother Cancer

Age	1.30	0.99, 1.71	0.056
Clark	1.32	1.06, 1.67	0.016
Thickness	1.29	0.95, 1.75	0.097